- Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH.
- Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids.
- Key opinion leaders’ discussion highlights new data and is available on demand.
Oramed Announces Additional Safety, Efficacy Data From Phase 2 Clinical Trial Of ORMD-0801 For NASH; Achieved Primary Endpoint
Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH.
Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat,
